Screening Archive
60일이 지난 screening 항목 아카이브입니다. 최근 screening으로 돌아가기.
총 45건.
2026-07-13 (45건)
- Association of high-risk CT coronary artery plaque features with major adverse cardiovascular events: a prespecified secondary analysis of the DISCHARGE trial. — include / 0.75 · European radiology · PMID 41686241
- Large language model and Gd-EOB-DTPA-enhanced MRI-based risk stratification system for postoperative hepatocellular carcinoma: a multicenter study. — include / 0.90 · European radiology · PMID 41731093
- A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer. — include / 0.92 · Cancer discovery · PMID 41747244 · 📎 Zotero
- PET/CT predict pathological response to neoadjuvant nivolumab in resectable non-small cell lung cancer. — include / 0.90 · European journal of nuclear medicine and molecular imaging · PMID 41792564
- Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial. — include / 0.90 · European journal of nuclear medicine and molecular imaging · PMID 41801367 · 📎 Zotero
- Beyond whole-image learning: anatomically partitioned deep learning models for superior sinonasal disease classification. — include / 0.85 · European radiology · PMID 41832258 · 📎 Zotero
- A deep learning PET/CT biomarker for early progression (POD24) and survival stratification in follicular lymphoma: a multicenter study. — include / 0.92 · European journal of nuclear medicine and molecular imaging · PMID 41870550 · 📎 Zotero
- Neuro-visceral immunometabolic network phenotyping via baseline whole-body [¹⁸F]FDG PET/CT underlying pathologic response to neoadjuvant immunochemotherapy in resectable NSCLC. — include / 0.90 · European journal of nuclear medicine and molecular imaging · PMID 41885941 · 📎 Zotero
- [177Lu]Lu-DOTA-IBA plus EGFR-TKIs versus [177Lu]Lu-DOTA-IBA monotherapy for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) with bone metastases: a prospective study. — include / 0.90 · European journal of nuclear medicine and molecular imaging · PMID 41915037 · 📎 Zotero
- Imaging-based stratification of Claudin 18.2-positive gastric adenocarcinoma using 18F-FDG PET/CT radiomics. — include / 0.90 · European journal of nuclear medicine and molecular imaging · PMID 41942650 · 📎 Zotero
- Ternary classification prediction and heterogeneity quantification for HER2-Zero, -low, and -positive in breast cancer using HER2-targeted PET/CT imaging. — include / 0.95 · European journal of nuclear medicine and molecular imaging · PMID 41995838 · 📎 Zotero
- Clinical outcomes and tumor immune microenvironment in SMARCA4-Deficient NSCLC: A Real-World retrospective study. — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42066656
- Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy. — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42066657
- Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients. — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42068890 · 📎 Zotero
- Clinical impact of local consolidative therapy in EGFR-mutant metastatic NSCLC: A propensity-matched multicenter analysis. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42068892 · 📎 Zotero
- Protective effect of bevacizumab against interstitial lung disease in non-squamous non-small-cell lung cancer: a nationwide target trial emulation study. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42081857
- Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion). — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42096800 · 📎 Zotero
- Upfront management of brain metastases in oncogene‑addicted NSCLC - An EORTC survey. — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42114373 · 📎 Zotero
- Insights from a randomized controlled trial on a digital lifestyle intervention in non-small cell lung cancer survivors following inpatient rehabilitation. — maybe / 0.65 · Lung cancer (Amsterdam, Netherlands) · PMID 42127533 · 📎 Zotero
- Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42127534
- Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer. — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42127535 · 📎 Zotero
- Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42134157
- An interpretable PET/CT-based radiomic-clinical model for predicting bone marrow involvement in follicular lymphoma: comparison of pelvic and spine-pelvis VOI frameworks. — include / 0.92 · European journal of nuclear medicine and molecular imaging · PMID 42142271
- Patient and clinician preferences for adjuvant treatment following surgical resection in early-stage non-small cell lung cancer: A multi-country discrete choice experiment. — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42143519 · 📎 Zotero
- Patient and caregiver priorities of treatment characteristics influencing preferences for tyrosine kinase inhibitors in anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer. — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42143874 · 📎 Zotero
- OX40+ regulatory T cells suppress neoadjuvant chemotherapy response in NSCLC and reversed by combination of PD-1 blockade therapy. — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42150482
- Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN). — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42150483 · 📎 Zotero00515-5/pdf)
- Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42155306
- Clinical characteristics and survival of small cell lung cancer with limited or extensive synchronous metastatic spread - A German population-based cancer-registry based cohort study. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42167027 · 📎 Zotero00509-X/pdf)
- Study on NGS-based molecular profiling of malignant pleural effusion supernatant cfDNA in guiding targeted therapy for non-small cell lung cancer. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42172737 · 📎 Zotero
- First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42214242
- Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42214243
- Rare EGFRm NSCLC: More First-Line Options Emerge. — include / 0.90 · Cancer discovery · PMID 42224429
- Selpercatinib Improves EFS in RET Fusion-Positive NSCLC. — include / 0.95 · Cancer discovery · PMID 42226675
- Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42229337 · 📎 Zotero
- Cardiovascular adverse events in non-small cell lung cancer patients receiving osimertinib therapy: a systematic review and meta-analysis. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42229338
- Reply to Qu et al.: Do mtDNA fragmentomic peaks reflect cancer biology or preanalytical and technical artifacts in NSCLC? — include / 0.85 · American journal of respiratory and critical care medicine · PMID 42391029
- Do mtDNA fragmentomic peaks reflect cancer biology or preanalytical and technical artifacts in NSCLC? — include / 0.85 · American journal of respiratory and critical care medicine · PMID 42393493
- Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy. — include / 0.85 · Lung cancer (Amsterdam, Netherlands) · PMID 42398475 · 📎 Zotero
- ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model. — include / 0.90 · Lung cancer (Amsterdam, Netherlands) · PMID 42407241
- Lung Transplant for Refractory Lung-Limited Stage IV Non-Small Cell Lung Cancer. — include / 0.90 · JAMA · PMID 42418196
- Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. — include / 0.95 · The New England journal of medicine · PMID 42418775
- Clinical significance of CD161+CD8+ T cells in the tumor microenvironment of esophageal squamous cell carcinoma and their association with the 4-1BB signaling pathway. — include / 0.85 · Journal for immunotherapy of cancer · PMID 42425714 · 📎 Zotero
- Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC. — include / 0.90 · Journal for immunotherapy of cancer · PMID 42425715 · 📎 Zotero
- From center to edge: Prognostic implications of spatial metabolic heterogeneity, normalized hotspot-to-centroid and perimeter distance, on PET imaging. A systematic review and meta-analysis. — include / 0.90 · European journal of nuclear medicine and molecular imaging · PMID 42429822